Cargando…
Sa1390: THE EFFICACY OF ELBASVIR/GRAZOPREVIR FIXED-DOSE COMBINATION FOR 8 WEEKS IN HCV TREATMENT AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN TREATMENT-NAIVE, NON-CIRRHOTIC, GENOTYPE 4-INFECTED PATIENTS (ELEGANT-4)
Autores principales: | AlEid, Ahmad, Balkhi, Areej Al, Alqutub, Adel, Abbarh, Shahem, Allehibi, Abed, Almtawa, Abdullah, Alotaibi, Nawwaf, Alghamdi, Ahmed G., AlGhamdi, Adel, Alamr, Abdulrahman, Ahmad, Shameem, Alsayari, Khalid, AlIbrahim, Bashaar, Khathlan, Abdullah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212490/ http://dx.doi.org/10.1016/S0016-5085(22)63449-8 |
Ejemplares similares
-
The efficacy of Elbasvir/Grazoprevir fixed-dose combination for 8 weeks in HCV treatment and health-related quality of life (HRQoL) in treatment-naïve, non-cirrhotic, genotype 4-infected patients (ELEGANT-4): A single-center, single-arm, open-label, phase 3 trial
por: AlEid, Ahmad, et al.
Publicado: (2022) -
Prevalence and Risk Factors of Cytomegalovirus Colitis in Inflammatory Bowel Disease Patients in Riyadh, Saudi Arabia: A Tertiary Center Experience
por: Alotaibi, Yazeed, et al.
Publicado: (2023) -
Peripancreatic fluid collections, plastic stents, and different sub-types of metal stents: Where does the evidence land?
por: Al Lehibi, Abed, et al.
Publicado: (2020) -
Peroral endoscopic myotomy (POEM) for the treatment of achalasia: A multicenter Middle Eastern experience
por: Al Lehibi, Abed, et al.
Publicado: (2021) -
Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient
por: Chen, Jin, et al.
Publicado: (2020)